|Bid||4.02 x 1500|
|Ask||4.74 x 1000|
|Day's range||4.05 - 4.16|
|52-week range||2.06 - 5.18|
|PE ratio (TTM)||-15.15|
|Earnings date||13 Nov 2017 - 17 Nov 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||9.00|
On August 14 2017, BrainStorm (BCLI) announced financial results for the second quarter of 2017. As expected, the company did not report any revenue. The increase was due to an increase in payroll and stock-based compensation partially offset by a decrease in costs related to the U.S. clinical trial.
NEW YORK, NY / ACCESSWIRE / August 16, 2017 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q2 Earnings Call to be held August 16, 2017 at 8:30 AM ...
Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 15, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics ...